TOP TEN perturbations for 1554514_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1554514_at
Selected probe(set): 89977_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1554514_at (89977_at) across 6674 perturbations tested by GENEVESTIGATOR:

hepatocyte (ESC) / HepaRG

Relative Expression (log2-ratio):-5.588195
Number of Samples:8 / 12
Experimental hepatocyte (ESC)
Hepatocyte-like cells differentiated from embryonic stem cells (ESC)
Control HepaRG
Immortalized cancer cell line derived from female patient with hepatocellular carcinoma. Cells can be induced to differentiate into hepatocyte-like cells by exposure to DMSO. Synonyms:Hepa-RG Cellosaurus code:

Hep-G2 / HepaRG

Relative Expression (log2-ratio):-4.8258066
Number of Samples:9 / 12
Experimental Hep-G2
Human primary cancer cell line derived from the liver of a patient with hepatocellular carcinoma. Synonyms:HEP-G2; Hep G2; HEP G2; HepG2; HEPG2 Cellosaurus code:
Control HepaRG
Immortalized cancer cell line derived from female patient with hepatocellular carcinoma. Cells can be induced to differentiate into hepatocyte-like cells by exposure to DMSO. Synonyms:Hepa-RG Cellosaurus code:

4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone study 1 (7500 uM; HepaRG) / vehicle (DMSO) treated HepaRG cell sample

Relative Expression (log2-ratio):-4.417391
Number of Samples:3 / 12
Experimental 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone study 1 (7500 uM; HepaRG)
HepaRG cells exposed to 7500 uM 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (dissolved in 0.5% v/v DMSO) for 72 hours. Cells were cultivated in DMSO-containing medium between days 13 - 19 to allow them to differentiate into hepatocyte-like cells and become fully functional. Chemical was added at day 19 of cultivation. Cells were treated with the IC10 determined by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide test (number of replicates, n = 3). ATC code:---
Control vehicle (DMSO) treated HepaRG cell sample
HepaRG cells treated with vehicle (DMSO 0.5% v/v) for 72 hours. Firstly, cells were cultivated in DMSO-containing medium between days 13 - 19 to allow them to differentiate into hepatocyte-like cells and become fully functional. Then the vehicle was added.

HCC study 9 (HBV; HCV) / normal liver tissue

Relative Expression (log2-ratio):-3.857913
Number of Samples:2 / 10
Experimental HCC study 9 (HBV; HCV)
Liver tissue biopsy sample from patients with Hepatitis B and C infection related hepatocellular carcinoma (HCC) after resection.
Control normal liver tissue
Normal, non-tumor liver tissue.

hepatoblastoma study 1 (embryonal) / normal liver tissue

Relative Expression (log2-ratio):-3.5337849
Number of Samples:7 / 5
Experimental hepatoblastoma study 1 (embryonal)
Liver tumor tissue samples from children with hepatoblastoma (epithelial type (E-HB); embryonal subtype). Tumors were integrase interactor 1–negative (INI1 or SMARCB1) as recommended by the International ConsensusHBClassification group.
Control normal liver tissue
Normal liver tissue samples.

HCC study 18 (very advanced) / normal liver tissue

Relative Expression (log2-ratio):-3.4950142
Number of Samples:3 / 10
Experimental HCC study 18 (very advanced)
Tumor tissue samples obtained from liver of patients with very advanced hepatocellular carcinoma (HCC) undergoing resection or liver transplantation. Very advanced HCC cases included moderately to poorly differentiated tumors with macrovascular invasion or diffuse liver involvement. Patients positive for HBV markers, with history of alcohol consumption, nonalcoholic steatohepatitis, hemochromatosis, other chronic liver diseases or prior locoregional treatment were excluded.
Control normal liver tissue
Normal liver tissue samples obtained from the healthy livers of patients undergoing resection for hepatic hemangioma, focal nodular hyperplasia, adenoma/cystadenoma, neuroendocrine tumor, and living donor liver transplantation.

HIF-1a/HIF-2a depletion study 1 (normoxia; AB81) / HIF-1a depletion study 2 (normoxia; AB81)

Relative Expression (log2-ratio):-3.4524984
Number of Samples:3 / 3
Experimental HIF-1a/HIF-2a depletion study 1 (normoxia; AB81)
Human podocyte cells AB81 with shRNA-mediated stable knock-down of HIF-1a and HIF-2a (Hypoxia-inducible factor 1-alpha and Hypoxia-inducible factor 2-alpha) 24 hours after treatment with normoxia (20% O2). Conditionally immortalized human podocytes AB81 were cultured under permissive conditions (33 °C) in RPMI-1640 supplemented with 10% FBS, antibiotics, and 1% ITS. Differentiation was induced by thermoshift to 37 °C in 6-well plates.
Control HIF-1a depletion study 2 (normoxia; AB81)
Human podocyte cells AB81 with shRNA-mediated stable knock-down of HIF-1a (Hypoxia-inducible factor 1-alpha) 24 hours after treatment with normoxia (20% O2). Conditionally immortalized human podocytes AB81 were cultured under permissive conditions (33 °C) in RPMI-1640 supplemented with 10% FBS, antibiotics, and 1% ITS. Differentiation was induced by thermoshift to 37 °C in 6-well plates.

HCC study 27 (young; training) / normal liver tissue (young; training)

Relative Expression (log2-ratio):-3.3901243
Number of Samples:16 / 15
Experimental HCC study 27 (young; training)
Primary tumor tissue samples obtained from the liver of young patients (≤ 40 years old) with hepatocellular carcinoma assigned to a training cohort.
Control normal liver tissue (young; training)
Normal liver tissue samples obtained from young patients (≤ 40 years old) with hepatocellular carcinoma (HCC) assigned to a training cohort.

HCC study 18 (very advanced) / HCC study 18 (very early)

Relative Expression (log2-ratio):-3.3302755
Number of Samples:3 / 5
Experimental HCC study 18 (very advanced)
Tumor tissue samples obtained from liver of patients with very advanced hepatocellular carcinoma (HCC) undergoing resection or liver transplantation. Very advanced HCC cases included moderately to poorly differentiated tumors with macrovascular invasion or diffuse liver involvement. Patients positive for HBV markers, with history of alcohol consumption, nonalcoholic steatohepatitis, hemochromatosis, other chronic liver diseases or prior locoregional treatment were excluded.
Control HCC study 18 (very early)
Tumor tissue samples obtained from liver of patients with very early hepatocellular carcinoma (HCC) undergoing resection or liver transplantation. Very early HCC cases included well-differentiated tumors measuring ≤2 cm in diameter with no vascular invasion/satellites (size range: 8-20 mm). Patients positive for HBV markers, with history of alcohol consumption, nonalcoholic steatohepatitis, hemochromatosis, other chronic liver diseases or prior locoregional treatment were excluded.

HCC study 23 (portal vein infiltration) / adjacent liver tissue

Relative Expression (log2-ratio):-3.2557726
Number of Samples:3 / 10
Experimental HCC study 23 (portal vein infiltration)
Tumor liver tissue samples derived from patients with hepatocellular carcinoma (HCC) with portal vein infiltration. Samples were derived by laser capture microdissection (LCM) from patients with HCC from the Chinese National Human Genome Center at Shanghai.
Control adjacent liver tissue
Normal adjacent liver tissue samples derived from patients with hepatocellular carcinoma (HCC). Samples were derived by laser capture microdissection (LCM) from patients with HCC from the Chinese National Human Genome Center at Shanghai.